drugset
drugset / Trial / NCT01965613

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

NCT01965613 ↗

Phase 2 Completed 10 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

Timeline

Start
2014-01-31
Primary completion
2016-12-31
Completion
2016-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bermekimab Monoclonal antibody — —

Indications

pyoderma gangrenosum